Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pieris Pharmaceuticals, Inc. (PIRS : NSDQ)

• Company Description    Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. Number of Employees: 141

• Price / Volume Information    Yesterday's Closing Price: $1.69 Daily Weekly Monthly 20 Day Moving Average: 567,971 shares Shares Outstanding: 74.10 (millions) Market Capitalization: $125.23 (millions) Beta: 1.19 52 Week High: $6.15 52 Week Low: $1.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -45.48% -40.26% 12 Week -47.19% -42.70% Year To Date -55.29% -46.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 255 State Street 9th Floor - Boston,MA 02109 USA ph: 857-246-8998 fax: 49-8161-141-1444 kelman@pieris.com http://www.pieris.com

• General Corporate Information    Officers Stephen S. Yoder - President; Chief Executive Officer James Geraghty - Chairman Thomas Bures - Chief Financial Officer Michael Richman - Director Maya R. Said - Director Peer Information Pieris Pharmaceuticals, Inc. (CORR.) Pieris Pharmaceuticals, Inc. (RSPI) Pieris Pharmaceuticals, Inc. (CGXP) Pieris Pharmaceuticals, Inc. (BGEN) Pieris Pharmaceuticals, Inc. (GTBP) Pieris Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 720795103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 74.10 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $125.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.34 Price/Cash Flow: - Price / Sales: 4.68 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 46.15% Sales Growth vs. Year Ago Period: -29.71% vs. Previous Quarter: 30.14% ROE 03/31/22 - -92.04 12/31/21 - -97.46 09/30/21 - -120.25 ROA 03/31/22 - -30.90 12/31/21 - -31.39 09/30/21 - -37.82 Current Ratio 03/31/22 - 2.83 12/31/21 - 2.52 09/30/21 - 2.77 Quick Ratio 03/31/22 - 2.83 12/31/21 - 2.52 09/30/21 - 2.77 Operating Margin 03/31/22 - -175.99 12/31/21 - -147.01 09/30/21 - -205.44 Net Margin 03/31/22 - -175.99 12/31/21 - -147.01 09/30/21 - -205.44 Pre-Tax Margin 03/31/22 - -174.31 12/31/21 - -145.58 09/30/21 - -202.97 Book Value 03/31/22 - 0.72 12/31/21 - 0.70 09/30/21 - 0.75 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©